Practical aspects of treatment with target specific anticoagulants: initiation, payment and current market, transitions, and venous thromboembolism treatment

Journal of Thrombosis and Thrombolysis

Volumn 39, Issue 3, 2015, Pages 295-303

  Mahan, Charles E ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Non valvular atrial fibrillation; Prevention; Stroke; Target specific oral anticoagulants; Treatment; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; EDOXABAN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; WARFARIN; BLOOD CLOTTING FACTOR 10A INHIBITOR;

ARTICLE; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; KIDNEY FUNCTION; LUNG EMBOLISM; MAXIMUM PLASMA CONCENTRATION; OUTPATIENT CARE; PRIORITY JOURNAL; REIMBURSEMENT; RISK REDUCTION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; UNITED STATES; VENOUS THROMBOEMBOLISM; ECONOMICS; HIP ARTHROPLASTY; KNEE ARTHROPLASTY; PULMONARY EMBOLISM; STROKE; VENOUS THROMBOSIS;

ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; FACTOR XA INHIBITORS; HUMANS; PULMONARY EMBOLISM; STROKE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 84925482063     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-014-1164-4     Document Type: Article

References (33)

1. Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, Luan P, Hutchaleelaha A, Inagaki M, Conley PB, Phillips DR, Sinha U (2013) A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 19(4):446–451. doi:10.1038/nm.3102
2. Schiele F, van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, Nar H, Litzenburger T (2013) A specific antidote for dabigatran: functional and structural characterization. Blood 121(18):3554–3562. doi:10.1182/blood-2012-11-468207
3. Mahan CE, Fanikos J (2011) New antithrombotics: the impact on global health care. Thromb Res 127(6):518–524. doi:10.1016/j.thromres.2011.03.022
4. Weitz JI, Eikelboom JW, Samama MM, American College of Chest P (2012) New antithrombotic drugs: antithrombotic therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e120S–e151S. doi:10.1378/chest.11-2294
5. http://www.xareltohcp.com/sites/default/files/pdf/xarelto_0.pdf-zoom=100. Xarelto Package Insert. Accessed 12 Feb 2014
6. http://packageinserts.bms.com/pi/pi_eliquis.pdf. Eliquis Package Insert. Accessed 12 Feb 2014
7. http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/PrescribingInformation/PIs/Pradaxa/Pradaxa.pdf. Pradaxa Package Insert. Accessed 12 Feb 2014
8. http://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/006065.html. Edoxaban FDA submission. Accessed 12 Feb 2014
9. http://www.portola.com/clinical-development/andexanet-alfa-prt4445-fxa-inhibitor-antidote/. Andexanet Alpha Xa Reversal Agent. Accessed 12 Feb 2014
10. http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2014/19_november_2014dabigatranetexilateaha.html. Idarucizumab–Pradaxa Reversal Agent. Accessed 12 Feb 2014
11. http://www.jnj.com/news/all/Janssen-Expands-EXPLORER-Global-Cardiovascular-Research-Program-to-Evaluate-the-Role-of-XARELTO-in-Addressing-Critical-Medical-Needs. Rivaroxaban research programs. Accessed 12 Feb 2014
12. http://clinicaltrials.gov/ct2/results?term=apixaban&Search=Search. Apixaban clinical trials. Accessed 12 Feb 2014
13. http://clinicaltrials.gov/ct2/results?term=rivaroxaban&Search=Search. Rivaroxaban clinical research. Accessed 12 Feb 2014
14. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P, European Heart Rhythm A (2013) European heart rhythm association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 15(5):625–651. doi:10.1093/europace/eut083
15. Hokusai VTEI, Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369(15):1406–1415. doi:10.1056/NEJMoa1306638
16. Bang OY, Hong KS, Heo JH, Koo J, Kwon SU, Yu KH, Bae HJ, Lee BC, Yoon BW, Kim JS (2014) New oral anticoagulants may be particularly useful for asian stroke patients. J Stroke 16(2):73–80. doi:10.5853/jos.2014.16.2.73
17. Source: IMS Health National Prescription Audit, data through 11/14/14. Courtesy Janssen Pharmaceuticals 12/1/2014
18. http://www.eliquis.com/eliquis/support-coverage-assistance. Apixaban coverage. Accessed 12 March 2014
19. http://www.xareltohcp.com/formulary-map.html. Xarelto formulary map. Accessed 12 March 2014
20. http://www.xareltohcp.com/access-affordability/access-affordability.html. Xarelto Access and Affordability. Accessed 12 March 2014
21. http://www.pradaxapro.com/pradaxalink/dabigatran-coverage-affordability. Pradaxa coverage. Accessed 12 March 2014
22. http://www.fingertipformulary.com/drugs/Eliquis/. Eliquis Coverage by State. Accessed 12 March 2014
23. http://www.xareltocarepath.com/reducing-stroke-risk/xarelto-savings-programs. Xarelto savings programs. Accessed 12 March 2014
24. http://www.eliquis.com/eliquis/support-offers. Eliquis support programs. Accessed 12 March 2014
25. http://www.pradaxa.com/patient-support/pradaxalink.html. Pradaxa support programs. Accessed 12 March 2014
26. http://oig.hhs.gov/fraud/docs/alertsandbulletins/2014/SAB_Copayment_Coupons.pdf. Office of inspector general special advisory bulletin. Accessed 12 March 2014
27. Abo-Salem E, Becker R (2014) Transitioning to and from the novel oral anticoagulants: a management strategy for clinicians. J Thromb Thrombolysis 37(3):372–379. doi:10.1007/s11239-014-1060-y
28. Atay JK, Fiumara K, Piazza G, Fanikos J, Goldhaber SZ (2012) Hospital budget implications of substituting dabigatran for warfarin in an anticoagulation service. Clin Appl Thromb/Hemost 18(2):181–184. doi:10.1177/1076029611416642
29. Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, Dunn AS, Kunz R, College American, Chest P (2012) Perioperative management of antithrombotic therapy: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e326S–e350S. doi:10.1378/chest.11-2298
30. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM, Investigators EA-T (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369(22):2093–2104. doi:10.1056/NEJMoa1310907
31. Dawes J, Prowse CV, Pepper DS (1986) Absorption of heparin, LMW heparin and SP54 after subcutaneous injection, assessed by competitive binding assay. Thromb Res 44(5):683–693
32. Mahan CE, Borrego ME, Woersching AL, Federici R, Downey R, Tiongson J, Bieniarz MC, Cavanaugh BJ, Spyropoulos AC (2012) Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates. Thromb Haemost 108(2):291–302. doi:10.1160/TH12-03-0162
33. http://www.health.gov/hai/prevent_hai.asp. Nosocomial infections. Accessed 12 May 2014